SEATTLE, Sept. 7, 2023 /PRNewswire/ — CBDW AI, a brand of 1606 Corp. (OTC: CBDW) and the new prominent provider of enterprise-level artificial intelligence (AI) solutions tailored for the CBD industry, is thrilled to reveal its strategic partnership with AR XTLabs, a leading backend development firm. The collaboration aims to construct an advanced AI Natural Language Processing (NLP) Chatbot, specially designed for the CBD sector.

The CBDW AI product is being strategically engineered to elevate customer interactions, deliver an educational resource, facilitate new customer engagement, and offer CBD product recommendations. The primary objective of the CBDW AI is to bolster sales for CBD industry enterprises while ensuring an immensely enjoyable customer journey.

CBDW AI’s strategic vision includes licensing this technology within the United States to CBD brands and retailers.

The innovative AI project in development leverages the power of NLP, integrating computational linguistics (CL), machine learning, and deep learning models to comprehensively analyze human language. It promises to empower CBD consumers by assisting them in making informed product decisions based on their queries concerning CBD usage requirements. Over the years, CBD consumers have often faced uncertainty when navigating the plethora of choices and their perceived lack of knowledge about CBD usage. The CBDW AI solution is poised to address and resolve these long-standing customer choice issues, making the process of buying CBD products significantly more consumer-friendly.

“This is a new day for CBDW AI. We’re expanding our reach in the CBD industry to include enterprise customer service solutions for the growing number of online CBD consumers and brands. For a long time, choosing products online has always been difficult for CBD consumers and we aim to solve that problem with our new AI Customer experience Chatbot. This bot is a game changer for the entire industry because of the fragmentation of the industry. There are so many product choices that it’s daunting for consumers to make a choice. In leu of FDA approval, we aim to provide customers with a high degree of confidence when choosing CBD products,” said Greg Lambrecht, CEO of 1606 Corp.

About AR XTLabs; 

AR XTLabs, a new jersey Corporation, is a world leader in developing AI-enabled products and services for enterprise customers. Founded in the cloud era, our solutions are cloud-native and are capable of running on all three major cloud providers. The solutions we offer have been implemented in Fortune 100 companies across the Financial Services, Digital media, High-tech, Telecom, and Pharma sectors. The AR XTLabs team consists of serial entrepreneurs and experienced professionals who have successfully implemented an AI-Enabled mortgage closing process in partnership with a national title insurance company. AR XTLabs has offices in Seattle, Florida, and India. (https://arxtlabs.com)

About 1606 Corp – Bridging Today and Tomorrow with Innovative Technology

At 1606 Corp, we are not just a CBD company; we are a dynamic think tank with innovative technology solutions that are aimed at solving the top online customer service problems in the CBD industry. Established as an acquisition-based company, CBDW AI has developed a vision to redefine the CBD industry through both acquisitions and technology development. 1606 Corp stands at the intersection of cutting-edge technology and visionary collaborations to help you, the CBD consumer. Our mission is clear – to revolutionize the CBD industry by seamlessly integrating technology into the core operations of all CBD companies in the United States. We strive to empower businesses, both large and small, with enterprise solutions that drive efficiency, foster online sales growth, and open doors to unprecedented education and usage by CBD customers.

Industry Information;

Rates of cannabidiol (CBD) usage in the United States are projected to surge in 2023, according to Stirling CBD. With recent studies suggesting as high as a 10% year-over-year (YoY) increase in usage, Stirling CBD predicts that 2023 will be a pivotal year for the industry as the widespread adoption of CBD-infused products is set to take place across the health and wellness, beauty, and food and beverage industries.

Data from 2022 provides insight into the widespread nature of CBD-infused products. The Center for Advancing Health (CFAH) reported that 26% of Americans used CBD in 2022, and according to ClevelandClinic.org, 42% of people who take CBD use it for sleep-related reasons. It is also often marketed toward individuals struggling with anxiety, depression, quitting smoking, fitness recovery, and post-traumatic stress disorder (PTSD).

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief, or current expectations of 1606 Corp (the “Company”), its directors, or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the Company’s control and which could, and likely will materially affect actual results, levels of activity, performance, or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

BYND Cannasoft Subsidiary Zigi Carmel Initiatives & Investments LTD. filed US Provisional Patent Application 63/450,503 on March 7, 2023 covering the mechanical structure, operation, and controlling aspects of an additional smart female treatment device

ASHKELON, Israel and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today plans to enter the multibillion-dollar Sextech Industry as its Zigi Carmel Initiatives & Investments subsidiary filed a U.S. Provisional Patent Application for an additional smart female treatment device for external use. The new artificial intelligence (AI) based device will be capable of treating certain phenomena in female sexual organs. Sextech is a $30 billion industry today, however, according to an analysis report, the industry should grow to $52.7 billion by 2026 with a huge assist from online sales.ⁱ The company plans to develop the new AI based device as well as its EZ-G device.

The device utilizes an artificial intelligence and machine learning algorithms to control the operational parameters of the device based on physiological parameters of the user. The device performs operations including stimulating the sexual organs based on user preferences as well as real time data indicative of satisfaction level of the user monitored by sensors. The patent application covers AI that stores user preference data and uses that data to learn general preferences and current operation preferences. This AI component will collect data on the response to various operation parameters and adjust the user preference data accordingly to provide learning capabilities and fine tune its operation as it gets to know its user.

BYND Cannasoft’s believes this AI based device also has tremendous potential to capture significant market share as a sex toy, since the technology behind this patent application has the potential to improve the interaction between human and machine. The AI has the capability to collect data on the user’s response to vary stimulation patterns, determine lubricant dispensing rate, and determine sexual climax of the user by using artificial intelligence and machine learning based on data collected and the previous user’s response. This learned AI is designed to provide the user with a natural experience in a controlled manner based on user preferences and real time data. The device also includes a communication component that uses the data and information it has gathered from its sensors to create custom programs and upload the data to the cloud.

Yftah Ben Yaackov, CEO and Director of BYND Cannasoft said, “Our new AI based device comes at a pivotal time as most companies are changing their focus to connect with their customers in more automated and personalized ways. Real-time technologies and generative AI are paving the way for how consumers think and influencing the items they purchase. BYND Cannasoft intends to pursue the final registration of its patents and establish a marketing and sales system for our new AI device and the EZ-G device based on B2B and B2C sales.”

BYND previously announced it had filed US Provisional Patent Application number 63/297,009 on January 6, 2022 and PCT application number PCT/IL2023/050016 on January 5, 2023 covering the monitoring and controlling aspects of its EZ-G device. The EZ-G device is a therapeutic device combined with proprietary AI-based software that regulates the flow of low-concentration oils into the soft tissues of the female reproductive system. This process could prove beneficial to pain associated with trauma, complications from surgery or other medical procedures, vulvovaginal atrophy due to a drop of estrogen following menopause, vulvar vestibulitis related to a highly localized burning or cutting type of pain, and cervical cancer. The EZ-G device can utilize naturally derived oils, such as CBD and hempseed, as well as commercially manufactured varieties.

About BYND Cannasoft Enterprises Inc.

BYND Cannasoft Enterprises is an Israeli-based integrated software and cannabis company. BYND Cannasoft owns and markets “Benefit CRM,” a proprietary customer relationship management (CRM) software product enabling small and medium‐sized businesses to optimize their day‐to‐day business activities such as sales management, personnel management, marketing, call center activities, and asset management. Building on our 20 years of experience in CRM software, BYND Cannasoft is developing an innovative new CRM platform to serve the needs of the medical cannabis industry by making it a more organized, accessible, and price-transparent market. The Cannabis CRM System will include a Job Management (BENEFIT) and a module system (CANNASOFT) for managing farms and greenhouses with varied crops. BYND Cannasoft owns the patent-pending intellectual property for the EZ-G device. This therapeutic device uses proprietary software to regulate the flow of low concentrations of CBD oil, hemp seed oil, and other natural oils into the soft tissues of the female reproductive system to potentially treat a wide variety of women’s health issues. The EZ-G device includes technological advancements as a sex toy with a more realistic experience and the prototype utilizes sensors to determine what enhances the users’ pleasure. The user can control the device through a Bluetooth app installed on a smartphone or other portable device. The data will be transmitted and received from the device to and from the secure cloud using artificial intelligence (AI). The data is combined with other antonymic user preferences to improve its operation by increasing sexual satisfaction.

For Further Information please refer to information available on the Company’s website: www.cannasoft-crm.com, the CSE’s website: www.thecse.com/en/listings/life-sciences/bynd-cannasoft-enterprises-inc and on SEDAR: www.sedar.com.

Gabi Kabazo

Chief Financial Officer

Tel: (604) 833-6820

e‐mail: ir@cannasoft-crm.com

For Media and Investor Relations, please contact:

David L. Kugelman

(866) 692-6847 Toll Free – U.S. & Canada

(404) 281-8556 Mobile and WhatsApp

dk@atlcp.com

Skype: kugsusa

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving risks and uncertainties, which may cause results to differ materially from the statements made. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document, the words “may,” “would,” “could,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect,” “potential,” “continue,” “strategy,” “future,” “project,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward looking statements use these words or expressions. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our additional smart female treatment device , our Cannabis CRM platform, our expanded EZ-G patent application, our market growth, and our objectives for future operations, are forward looking statements. Additional regulatory standards may be required, including FDA approval or any other approval for the purpose of manufacturing, marketing, and selling the devices under therapeutic indications. There is no certainty that the aforementioned approvals will be received, and all the information in this release is forward-looking. Such statements reflect the company’s current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made, including unanticipated regulatory requests and delays, final patents approval, and those factors discussed in filings made by the company with the Canadian securities regulatory authorities, including (without limitation) in the company’s management’s discussion and analysis for the nine month period ended September 30, 2022 and annual information form dated October 8, 2022, which are available under the company’s profile at www.sedar.com, and in filings made with the U.S. Securities and Exchange Commission. Should one or more of these factors occur, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward‐looking statements, except as required by law. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Shareholders are cautioned not to put undue reliance on such forward‐looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The new full scale PCT application for the EZ-G device, comprised of a structure and one or more moving and vibrating elements, will utilize Artificial Intelligence (AI) to send data about learned sexual preferences to the cloud to heighten arousal, and intimacy

ASHKELON, Israel and VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company“) announced today that in addition to the US Provisional Patent Application with serial number 63/297,009 that was filed on January 6, 2022, covering the monitoring and controlling aspects of its EZ-G device, the company filed a full-scale PCT application on January 5, 2023, under serial number PCT/IL2023/050016. The PCT application is based on BYND Cannasoft’s prototype of the EZ-G device that is currently under development and its operational aspects as a learning adult device. The PCT application further claims priority from the US Provisional application and covers an adult device with a structure and one or more moving and vibrating elements.

In addition to potentially treating annoying phenomena in the female reproductive system, the EZ-G device includes technological advancements as a sex toy with a more realistic experience. The EZ-G device prototype uses sensors like a pressure sensor, temperature sensor, conductivity sensor, and heart rate sensor to determine what specifically enhances the users’ pleasure. The EZ-G device uses artificial intelligence (AI) to transmit and receive data from the device’s sensors on conditions of the user’s sexual organs, such as moisture levels and pressure variations due to muscle contraction. The EZ-G prototype includes a Bluetooth component for controlling the adult device via an app installed on a smartphone or other portable device to collect user information about preferences and generate custom programs. The data collected from the sensors is uploaded to the secured cloud, where it is combined with other antonymic user’s preferences, including the actual duration of operation of the adult device, lubrication level, and the ideal vibration level. This information optimizes the operation of the device to satisfy the user sexually. The EZ-G device uses the collected secured data to learn the users’ responses and improve its operation to bring the user sexual satisfaction.

Wearable tech has seen tremendous growth in recent years. When most people think of wearables, they think of fitness trackers and smartwatches, but there is also an emerging trend in wearable sex toys. The excitement of a sex toy and the thrill of clandestine public stimulation have contributed to this trend. Cannasoft intends to take advantage of the growth in the sextech market, which is expected to reach $62.32 by 2030. According to Forbes, companies are working to innovate products that have an intelligent response for sexual activity to take advantage of this expected growth.

Yftah Ben Yaackov, CEO and Director of BYND Cannasoft said, “The EZ-G device has evolved to provide treatment relief from sexual and mental problems, including the ability to have intercourse as it relates to anxiety and physical pain. The device is capable of enhancing sexual pleasure and reducing sexual pain by dispensing a low concentrations of CBD oil lubricant in a controlled manner. It could be configured to use disposable capsules that include the CBD lubricant, which could be dispensed in accordance with data collected by the sensors. The sale of the disposable capsules containing the CBD lubricant would provide BYND Cannasoft with a revenue model much like the razor and the razor blade.”

About BYND Cannasoft Enterprises Inc.

BYND Cannasoft Enterprises is an Israeli-based integrated software and cannabis company. BYND Cannasoft owns and markets “Benefit CRM,” a proprietary customer relationship management (CRM) software product enabling small and medium‐sized businesses to optimize their day‐to‐day business activities such as sales management, personnel management, marketing, call center activities, and asset management. Building on our 20 years of experience in CRM software, BYND Cannasoft is developing an innovative new CRM platform to serve the needs of the medical cannabis industry by making it a more organized, accessible, and price-transparent market. The Cannabis CRM System will include a Job Management (BENEFIT) and a module system (CANNASOFT) for managing farms and greenhouses with varied crops. BYND Cannasoft owns the patent-pending intellectual property for the EZ-G device. This therapeutic device uses proprietary software to regulate the flow of low concentrations of CBD oil, hemp seed oil, and other natural oils into the soft tissues of the female reproductive system to potentially treat a wide variety of women’s health issues. The EZ-G device includes technological advancements as a sex toy with a more realistic experience and the prototype utilizes sensors to determine what enhances the users’ pleasure. The user can control the device through a Bluetooth app installed on a smartphone or other portable device. The data will be transmitted and received from the device to and from the secure cloud using artificial intelligence (AI). The data is combined with other antonymic user preferences to improve its operation by increasing sexual satisfaction.

For Further Information please refer to information available on the Company’s website: www.cannasoft-crm.com, the CSE’s website: www.thecse.com/en/listings/life-sciences/bynd-cannasoft-enterprises-inc and on SEDAR: www.sedar.com.

Gabi Kabazo

Chief Financial Officer

Tel: (604) 833-6820

e‐mail: [email protected]

For Media and Investor Relations, please contact:

David L. Kugelman

(866) 692-6847 Toll Free – U.S. & Canada

(404) 281-8556 Mobile and WhatsApp

[email protected]

Skype: kugsusa

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving risks and uncertainties, which may cause results to differ materially from the statements made. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document, the words “may,” “would,” “could,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect,” “potential,” “continue,” “strategy,” “future,” “project,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward looking statements use these words or expressions. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding changes to our leadership team, our Cannabis CRM platform, our expanded EZ-G patent application, the expected benefits of our double-faceted condom design to users, our market growth, and our objectives for future operations, are forward looking statements. Additional regulatory standards may be required, including FDA approval or any other approval for the purpose of manufacturing, marketing, and selling the device under therapeutic indications. There is no certainty that the aforementioned approvals will be received, and all the information in this release is forward-looking. Such statements reflect the company’s current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made, including unanticipated regulatory requests and delays, final patents approval, and those factors discussed in filings made by the company with the Canadian securities regulatory authorities, including (without limitation) in the company’s management’s discussion and analysis for the nine month period ended September 30, 2022 and annual information form dated October 8, 2022, which are available under the company’s profile at www.sedar.com, and in filings made with the U.S. Securities and Exchange Commission. Should one or more of these factors occur, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward‐looking statements, except as required by law. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Shareholders are cautioned not to put undue reliance on such forward‐looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Announcement of distribution agreement coincides with appearance of both
companies at Arab Health 2022, the largest medical equipment exhibition in the Middle East

VANCOUVER, BC, Jan. 27, 2022 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) today announced that it has signed a distribution agreement with Dubai-based medical technology company Emitac Healthcare Solutions (“Emitac”). Under the terms of the agreement, Emitac has become an official distributor of CognICA, Cognetivity’s medical device product, in the Middle East region.

Emitac is a leading healthcare innovator and solutions provider in the Middle East, with over 45 years of experience in the healthcare industry. It boasts an impressive array of public- and private-sector organisations among its customers and clients, from Dubai Healthcare City and the United Arab Emirates Ministry of Health & Prevention to Cleveland Clinic, Samsung Ultrasound Systems and Philips Healthcare.

CognICA is Cognetivity’s flagship medical device product. It is a cutting-edge, computerized test of cognitive function that offers numerous advantages over traditional pen-and-paper examinations, such as its short testing duration and high classification accuracy, coupled with the absence of a learning effect or any cultural or educational bias.

CognICA is FDA-registered and CE-marked, and has already been commercially deployed across three continents, including within the UK’s National Health Service (NHS) and in the state-of-the-art Clemenceau Medical Center in Dubai. The new agreement grants Cognetivity access to Emitac’s wealth of experience and connections in the Middle East, as well as the full range of its customer support services, in order to bolster CognICA’s already-impressive commercial rollout in the region.

News of the partnership coincides with the appearance of both companies at Arab Health 2022. Taking place in Dubai from 24 to 27 January, Arab Health is the largest medical equipment exhibition in the Middle East, with exhibitors from over 60 countries participating and more than 56,000 healthcare professionals due to attend.

Cognetivity’s attendance at Arab Health and the burgeoning commercial rollout of CognICA across the Middle East come at a salient moment for the region. According to a study published this year in The Lancet Public Health, the UAE and other Gulf countries will experience the highest increases worldwide in the number of people living with dementia by 2050. This represents a major impending healthcare challenge, which cutting-edge technology such as Cognetivity’s will play a vital part in tackling.

Dr Sina Habibi, CEO of Cognetivity, said: “We’re delighted to have established this partnership with Emitac Healthcare Solutions. As its list of existing customers and clients shows, Emitac is a hugely-respected name in the region, bringing the experience and the manpower required to service our clientele and reassure customers of our commitment in this market.”

“Dementia poses a serious and widespread threat to the ageing population of the Middle East,” he added. “In order to stop dementia from turning into a healthcare crisis, we need to be bold and act fast. I am confident that this new agreement is the best way to accelerate our ongoing commercial rollout in the region and thoroughly excited about the positive impact it will have on patients’ lives.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

ON BEHALF OF THE BOARD
“Sina Habibi”
Sina Habibi
Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

Certain statements included in this news release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “assume” “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Cognetivity Neurosciences Ltd

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

For all of the talk about cannabis as a medicine and potential treatment for a wide variety of ailments, from sleep to stress to pain disorders and more, there is a huge missing element. There are almost no FDA-approved cannabis-derived medicines. The potential is very large considering the prevalence and market size of many of these conditions, so why aren’t we seeing more advanced drug candidates and approvals?

They are surely coming, but the hurdles are tremendous. Medical cannabis researchers are working in something of a vacuum, with little historical data to draw from due to years of prohibition. The plant itself is a highly complex assembly of active ingredients, or cannabinoids, and the mechanisms of action are not clearly understood. Genetics can vary widely from plant to plant, even within an accepted strain. Overall it seems there is more we don’t know about the plant than what we do. Data, and testing, and trials, and documentation, and interpretation are all sorely lacking.

RYAH Group, Inc. (CSE: RYAH) is here to change all of that with its suite of proprietary smart devices, patented AI-powered data engine, and its huge (and growing) database of medical cannabis use and its effects. RYAH is involved in several international clinical trials and studies, partnering with researchers to make their investigations efficient, productive, and scientifically relevant. RYAH’s data driven solutions are just the sort of medicine that cannabis researchers should be ordering in their quest to legitimize the plant as a pharmaceutical option.

The Intellectual Property

RYAH has been granted what it believes to be the first patent surrounding the use of artificial intelligence in plant-based medicine, including cannabis. Plant-based medicines are often seen as folk remedies, with practitioners relying on anecdotal evidence and a healthy dose of faith in their potential. There are occasional breakthroughs, like the discovery and development of aspirin, but plant-based medicine is in dire need of scientific documentation. And cannabis is perhaps at the head of that particular line right now.

RYAH CEO Greg Wagner discusses IP, including granted and pending patents.

 RYAH also has patents pending for its suite of connected devices – a pen for tinctures, a patch for transdermal applications, and an inhaler for breathable vapors. The devices offer precise and consistent session management for patients, something which can be difficult for people to achieve. They feed data about the volume and usage into an app, which also offers an easy way for users to record their experiences. The app is tied into the larger RYAH database, and the AI behind the system can make recommendations and observations based not only on the individual’s treatment history but on the history of thousands of other patients.

Put it all together and you have a cannabis- and plant-based medicine compendium of knowledge all wrapped up in the RYAH ecosystem. Patients, doctors, cultivators all benefit from the insights made possible by the system. And researchers are increasingly buying into the concept.

Click here to receive an investor presentation and corporate updates

RYAH and Scientific Research

The potential for RYAH’s proprietary system to move cannabis science forward is tantalizing. The more data is gathered, the more insights can be gained and the larger the body of knowledge becomes. RYAH devices are currently being used in a 5-year study in the United Kingdom, expected to cover thousands of patients and comprising one of the largest research projects to date on the efficacy of cannabis and hemp treatments of chronic pain.

Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. The combination of an IoT controlled device and direct API data integration with the Clinic’s Electronic Health Record (EHR) system is expected to enable scale and mitigate a number of variables associated with data collection and interpretation which are often performed manually for both volume measurement and patient feedback.

RYAH is also involved in a partnership with the University of Milan to develop a standardized dosing measurement system for dry herb. Think about it – how can doctors prescribe cannabis as a treatment without a method for standardizing the dosage? It’s this sort of foundational science that is needed to move cannabis into the medical mainstream, and RYAH’s system is just the type of solution to provide it.

RYAH is also involved in studies in Jersey, the largest of the Channel Islands between England and France. The company’s devices are central to a pilot study in Italy. The company has agreements in France and New Zealand. RYAH also publishes interesting monthly reports on preferences and tendencies based on user data, giving a glimpse of the kind of insights that can be gained.

In the end, RYAH is aggressively moving forward toward its goal of providing, collating, analyzing, and distributing the scientific data and information necessary to normalize cannabis based medical treatments. The opportunity is tremendous, and the need is dire. Those interested in the future of cannabis as a medicine are encouraged to find out more about RYAH Group Inc. (CSE: RYAH) and follow its progress.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has reached a commercial agreement (“ Agreement ”) with Cognetivity Neurosciences Ltd. (“ Cognetivity ”) (CSE: CGN; OTCQB: CGNSF; FWB: 1UB) for Cognetivity’s Integrated Cognitive Assessment (“ ICA ”) to be deployed in Ketamine One’s clinics across North America. The Company and Cognetivity have also entered into a non-binding letter of intent (the “ LOI ”) to collaborate on mental health assessments and plan on conducting clinical trials within Ketamine One’s network of clinics.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Pursuant to the terms of the Agreement, Ketamine One plans to deploy Cognetivity’s ICA across its network clinics to enable the long-term monitoring of cognitive performance in patients with treatment-resistant depression and post-traumatic stress disorder (“ PTSD ”). The ICA offers numerous benefits to clinicians, particularly in comparison to traditional, pen-and-paper-based tests. A computerized assessment that takes five minutes, the ICA is user-friendly and exhibits no learning effect upon repeat testing, making it perfectly suited to long-term monitoring.

The ICA is also highly sensitive to small changes in cognitive performance and, owing to its computerized nature, is capable of supporting remote, self-administered testing. Assessing individuals’ cognition over the course of their treatment will enable the measurement of treatment efficacy, while empowering patients to take charge of their wellbeing and providing clinicians with additional data to refine treatment and improve outcomes.

In addition to the ICA’s deployment in Ketamine One’s clinics, the LOI will see Cognetivity and Ketamine One collaborate on developing and validating next-generation mental health assessment tools to improve the lives of sufferers. The Company believes that Cognetivity offers a unique and technologically advanced assessment tool that can help standardize in clinic procedures and offer a powerful analytical element to Ketamine One’s digital therapeutic platform.

It is widely accepted that there is vast potential for improvement in the treatment of such conditions. According to the WHO, mental health disorders account for 28% of the global burden of disability-adjusted life years among non-communicable diseases – more than cardiovascular disease or cancer. Every year, more than 12 billion working days are lost due to mental health conditions, costing the global economy US$16 trillion in economic output between 2011 and 2030. The estimated addressable market size for anxiety disorder and depression treatments is US$238 billion.

Management Commentary

Dr. Sina Habibi, CEO of Cognetivity, said, “We’re very excited about this deployment, which will see the ICA used in clinical care in North America for the very first time. This is a key step in our plans for commercial rollout across the US and Canadian healthcare markets and indeed throughout the world. It is also fantastic to see the ICA making its mark in another area of medicine beyond its core use case of enhancing dementia detection and diagnosis,” he continued. “Our product’s ability to transition so effortlessly into this new and fast-growing space demonstrates the strength of its fundamental capabilities and the profound global need for accurate, efficient and unbiased cognitive testing in many new and emerging areas of research, detection and long-term patient monitoring.”

“The ICA technology will help Ketamine One improve and standardize both the initial assessment and the ongoing monitoring of patients with features not available in traditional paper-based surveys,” said Adam Deffett, Interim CEO of Ketamine One. “This tool will enable us to further demonstrate the power of our therapies and study patient development with an unwavering commitment to improve outcomes by putting more insightful data into the hands of our patients and clinicians. We are passionate about innovating in the pursuit of better mental health for our patients, and the ICA’s unique, AI-powered approach to measuring cognition matches our ethos perfectly,” added Mr. Deffett.

ABOUT COGNETIVITY NEUROSCIENCES LTD.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia. It has achieved regulatory approval for clinical use in the UK and Europe with future clinical approval anticipated in North America and elsewhere in the world.

For more information, please visit: www.cognetivity.com or contact: [email protected] .

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 24-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

“ Adam Deffett ”
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: [email protected]
Web: www.ketamine.one
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

In order for cannabis medicine to make the big leap to mainstream acceptance, a few things likely have to take place. Doctors, not just cannabis providers, need to become more comfortable discussing and prescribing the plant. Regulations need to become more homogenous and universal, like the pharmaceutical industry. Pharma companies need to advance more cannabis-derived medicines for approval.

In order for those things to happen, robust data around the efficacy of cannabis treatments needs to be gathered and widely understood. In the meantime, cannabis patients and providers are often stuck with a personal trial-and-error approach to finding the right treatment for their own needs. RYAH Group Inc. (CSE: RYAH) is one company that is pushing forward in all of these areas. The company’s smart delivery devices, database with over 200,000 users, and artificial intelligence-powered data engine combine to form a powerful Internet of Things solution with the potential to more fully legitimize cannabis medicine while making it more effective for current patients.

Moving the Industry Forward

Regulators like the United States Food and Drug Administration (FDA) need data to make informed decisions. Big pharma companies need data to even undertake research programs aimed at developing new potential drugs. Doctors need data to feel comfortable giving prescriptions or recommendations for treatment.

Since the cannabis industry is so young, was prohibited for so long, and still faces a myriad of patchwork and inconsistent regulations, cannabis medicine is severely lacking the large datasets that are crucial for the industry’s development. In this regard, RYAH is well-positioned to provide all interested parties with the information necessary for growth and advancement.

RYAH’s Data Sharing Benefits

The company’s smart devices and data solutions are gaining traction with cannabis researchers across the globe. The controlled dosing, easily recorded personal feedback from patients, wealth of data stored in RYAH’s Cloud database, and AI-powered data interpretation and organization give researchers tools that make their studies more effective and efficient. RYAH is involved in trials and studies in Britain, Italy, Italy again, and the Channel Islands. The company also has deals in France and New Zealand for distribution and potential inclusion in clinical trials and major studies.

RYAH’s goal is to provide regulators, researchers, and drug companies all the data they need to mainstream plant-based medicine, and it looks like the company is on its way.

Click here to receive an investor presentation and corporate updates

Improving the Patient Experience

RYAH’s smart devices, connected apps, and AI data interpreter can help patients and doctors effectively hone a treatment regimen according to the patient’s own feedback combined with that of the other users in the system. Without the insights from a large patient pool and the ability to easily record, track, and interpret personal experiences and preferences, many cannabis patients can get a little lost. Which strain? What is the proper dose? Has this particular type of treatment worked for other people?

Watch how Ryah technology Benefits to Patients and Doctors

RYAH’s system offers control and assurance, not only to researchers and patients involved in clinical trial programs but also to normal, everyday medical cannabis users in search of a little guidance. To many, using cannabis presents a great unknown fraught with risks. RYAH helps to alleviate those concerns and bring the cannabis patient experience more in line with that of conventional patients.

The Takeaway

This type of system is right in line with the larger trend toward tele-health and the use of machine learning and artificial intelligence to improve patient outcomes. Overall, the market for remote treatment is growing at a 26.5% CAGR, expected to reach $475 billion in the next five years. It’s a huge trend in healthcare, and RYAH is at the forefront of the movement in the cannabis industry.

The two aspects of RYAH’s business go hand in hand, improving treatments for cannabis patients while providing data and a platform that enables research and regulation that will further legitimize the industry as a whole. Keep an eye out for continued developments in the RYAH story.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to highlight the continued success of the Health Canada-approved NeuroCatch Platform (“NeuroCatch”) in use at its Integrated Rehab and Performance Ltd. (“IRP”) clinic in Victoria, BC. IRP has been an early adopter of NeuroCatch’s advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020. NeuroCatch continues to differentiate IRP from other rehabilitation clinics, along with its unique focus on patients from the Canadian Armed Forces, the Royal Canadian Mounted Police and various first responder organizations.

NeuroCatch is expected to remain a key part of IRP’s service offering as Ketamine One expands its network to new veteran-centric markets across Canada. Unique service offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time. Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. Psychedelics-focused research, a growing network of medical clinics, a broad suite of patient treatment options and leading technologies including digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One.

NeuroCatch:

In 2019, Health Canada approved the NeuroCatch Platform a class II medical device developed by HealthTech Connex Inc. that conducts a rapid 6-minute scan to measure and report on cognitive brain function. It is an easy-to-use, objective, rapid neuro-physiological brain function assessment system, that provides healthcare practitioners with objective measurements of specific brain functions: auditory sensation; basic attention and cognitive processing. Researchers and clinicians use this technology to gain insight into a range of common neurological conditions, including concussion and brain injury; dementia and neurological disease; post-traumatic stress disorder and mental health; and brain performance and human optimization.

Aside from its relationship with IRP, NeuroCatch is currently also collaborating or partnered with a long list of third parties including but not limited to Alberta Children’s Hospital, CAA Hockey, Canadian Space Agency, Equinox Integrative Wellness, Helius Medical Technologies, Kids Brain Health Network, Mayo Clinic, Toronto Rehabilitation Institute, University Health Network, University of Alberta, University of Calgary, University of Toronto, University of Victoria and Weill Cornell Medicine.

For more information about NeuroCatch, please visit www.neurocatch.com.

Management Commentary:

“Embracing technology is essential for improving our patients’ outcomes at IRP and giving them the best care throughout their healing and recovery processes. The use of NeuroCatch enables our staff to customize treatment plans and track improvements in brain health of our patients,” said Steven Inglefield, Founder & CEO of IRP. “Ketamine One’s continued integration of industry-leading clinics and the most advanced treatment options gives clinicians greater insights into every patient’s care, while the Company’s research assets provide the ability to stay at the forefront of breakthrough treatments and technologies,” added Mr. Inglefield.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

“Adam Deffett“
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: [email protected]

Web: www.ketamine.one

Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated.

MedXtractor Corp.’s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Let’s take a closer look at the challenges facing mental health treatments and how SHAMAN and psychedelics could play critical roles in improving them.

Mental Health Challenges

Mental health disorders affect a high percentage of the population. For example, mood and anxiety disorders affect nearly one-third of the U.S. population. In addition, a relatively high rate of people experiencing these conditions visit their primary care physician with physical complaints, like fatigue, creating an opportunity for diagnosis and treatment.

Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. For example, research shows that primary care physicians misdiagnosed 65.9% of patients with major depressive disorder, 92.7% of patients with bipolar disorder, 71% of patients with generalized anxiety disorder, and 97.8% of patients with social anxiety disorder.

Even if there’s an accurate diagnosis, many mental health treatments have less-than-desirable efficacy, and there can be significant side effects. Psychedelics could offer a better alternative for many patients. Still, years of prohibition have set back clinical trials, and there’s not a lot of information about how and when to administer these kinds of treatments.

Psychedelics Provide a Solution

Psychedelics have been used for thousands of years in religious ceremonies and as part of various cultures. These days, over 30 million people in the U.S. have used psychedelics for mystical experiences, curiosity, and introspection. The widespread use has made it clear that they don’t cause organ damage, withdrawal symptoms, or elicit compulsive use.

Researchers are just starting to uncover the potential for psychedelics to treat mental health disorders. For example, in a small study of adults with major depression, Johns Hopkins researchers found that two doses of psilocybin with psychotherapy produced rapid and significant reductions in depressive symptoms. Half of the participants were in complete remission through four weeks.

Despite the tremendous promise of psychedelics, there are no large-scale standardized clinical trials or data sources that clinicians can use to guide their patient decisions. Many studies thus far involve only a small number of participants and have a minimal focus without an eye toward mainstream applications at a clinical level.

Building the Data Backend

MedXtractor is leveraging machine learning to predict the impact of psychedelics and psychotropics on mental health disorders through its SHAMAN program. With extensive and ever-expanding validated data, the platform can provide high-resolution opinions on the probabilities related to many mental health afflictions.

Psychedelics and psychotropics and their potential application to mental health afflictions are SHAMAN’s initial target. In mid-June, the company announced that it has collected more than 400 complete reference records and is on track to reach its target of 500 complete reference records by June 30, 2021.

The company hopes to reach its Phase 3 target of 800 reference records by the end of August and launch the platform in December. In the meantime, management is focused on tight cost controls to keep project costs under budget while developing mHeath applications and their bio-extraction business operations.

Looking Ahead

Mental health disorders cost the global economy trillions of dollars each year, but screening, diagnosis, and treatment remain largely ineffective despite their prevalence. Psychedelics could play a role in turning around these trends, but clinicians require more data to properly diagnose patients and determine if psychedelic therapies are suitable for them.

MedXtractor Corp. (CSE: MXT) (OTC: MXTTF) is leveraging machine learning to garner insights from hundreds of complete medical records. Using these insights, the company hopes to provide high-resolution opinions on the probabilities related to many mental health afflictions.

Investors may want to take a closer look at the stock as it continues to collect complete reference records ahead of its launch late this year. For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Artificial intelligence has revolutionized computer science over the past decade. In fact, in a new paper submitted to the peer-reviewed Artificial Intelligence journal, scientists at the UK-based AI lab DeepMind argue that generalized intelligence will emerge from the reinforcement learning and reward maximization techniques already in use today.

While generalized intelligence remains elusive, the same algorithms that could eventually power it are already used in autonomous driving, chat bots, medical diagnostics, investing, price-setting and countless other applications. Grand View Research expects the global AI market to grow at a blistering 40.2% compound annual growth rate between 2021 and 2028.

Investors interested in the space may want to consider a number of different companies delivering hardware, software, or services.

#1. Cutting-edge Mental Health Applications

MedXtractor Corp. (CSE: MXT) aims to harness the power of artificial intelligence to identify mental health conditions via its SHAMAN program. Given the high rate of misdiagnosis in mental health, there’s a significant opportunity to improve patient outcomes in billion-dollar markets ranging from anxiety to depression to post-traumatic stress disorder.

Johns Hopkins found that 60% of people in a non-hospital setting were misdiagnosed with major depression while other studies have shown that bipolar disorder is similarly incorrectly diagnosed in many cases. In addition to unnecessary healthcare costs, many of these treatments lead to distraught patients and harmful side effects.

SHAMAN aims to provide practitioners, researchers and application developers with a fast and deep diagnostic tool. After collecting reference records consisting of extensive biometric data including EEG brain scans, machine-learning algorithms analyze and score records to create a Reference Database that forms the “memory” of the system.

Click here to receive an investor presentation and corporate updates 

AI algorithms learn from the core database—similar to the way that Tesla’s algorithms learn from real-time driving feedback— to make probabilistic predictions and form opinions. While humans may not see connections in these data clouds, these kinds of algorithms are built to make non-obvious connections that can improve diagnostic accuracy.

The company believes that its technology could work hand-in-hand with the nascent psychedelics market to not only predict probable mental illnesses and the potential effects of various drugs but incorporate psychedelics into the equation to deliver real results. The company also recently announced the development of a consumer mHealth application called YMI (why-am-I?”) that uses the same Reference Database as SHAMAN and that could drive significant growth ahead (the mHealth sector is growing rapidly and is expected to reach $160 billion over the next 6-7 years).

#2. Critical Hardware Components 

NVIDIA Corp. (NASDAQ: NVDA) may have begun its life as a chipmaker for video gamers, but GPUs have proven far more effective than CPUs at deep learning computation. While CPUs have a higher clock speed, GPUs have more processing cores for parallel computations, which are the cornerstone of both smooth graphics and artificial intelligence.

The company’s chips are used in both training and inference. For instance, the chips are used in cloud-based data centers where models are trained, as well as in self-driving cars where decisions are made on the spot. The company has also developed the world’s first portfolio of purpose-built AI supercomputers, the NVIDIA DGX, providing unparalleled performance.

#3. Diversified Exposure with an AI-Focused ETF

The Global X Robotics & Artificial Intelligence ETF (NASDAQ: BOTZ) invests in companies that stand to benefit from increased adoption and utilization of robotics and artificial intelligence. With nearly $2.6 billion in net assets and 32 different holdings, the exchange-traded fund provides both liquidity and diversified exposure to the space.

While the ETF may not have the upside potential of individual stocks, long-term investors can gain exposure to the market with a relatively low 0.68% expense ratio, although it’s significantly more volatile than the S&P 500 index and the MSCI EAFE. The ETF is up about 20% since its inception but has soared more than 80% over the past 52 weeks.

Click here to receive an investor presentation and corporate updates

Looking Ahead

Artificial intelligence and machine learning have revolutionized a growing number of industries. With greater processing power and availability of cloud services, companies will increasingly adopt these technologies to improve their products and services. Investors can participate via high-growth opportunities, like MedXtractor, or larger companies.

For more information about MedXtractor, download the investor presentation and receive updates.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.